JP2022527294A5 - - Google Patents

Info

Publication number
JP2022527294A5
JP2022527294A5 JP2021557609A JP2021557609A JP2022527294A5 JP 2022527294 A5 JP2022527294 A5 JP 2022527294A5 JP 2021557609 A JP2021557609 A JP 2021557609A JP 2021557609 A JP2021557609 A JP 2021557609A JP 2022527294 A5 JP2022527294 A5 JP 2022527294A5
Authority
JP
Japan
Prior art keywords
pharmaceutically acceptable
tautomer
compound according
unsubstituted
alkyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2021557609A
Other languages
English (en)
Japanese (ja)
Other versions
JP2022527294A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2020/024728 external-priority patent/WO2020198368A1/en
Publication of JP2022527294A publication Critical patent/JP2022527294A/ja
Publication of JP2022527294A5 publication Critical patent/JP2022527294A5/ja
Pending legal-status Critical Current

Links

JP2021557609A 2019-03-26 2020-03-25 Ｔｌｒシグナル伝達の調節剤としての化合物及び組成物 Pending JP2022527294A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201962824189P 2019-03-26 2019-03-26
US201962824170P 2019-03-26 2019-03-26
US62/824,170 2019-03-26
US62/824,189 2019-03-26
PCT/US2020/024728 WO2020198368A1 (en) 2019-03-26 2020-03-25 Compounds and compositions as modulators of tlr signaling

Publications (2)

Publication Number Publication Date
JP2022527294A JP2022527294A (ja) 2022-06-01
JP2022527294A5 true JP2022527294A5 (https=) 2023-04-03

Family

ID=70334086

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2021557609A Pending JP2022527294A (ja) 2019-03-26 2020-03-25 Ｔｌｒシグナル伝達の調節剤としての化合物及び組成物

Country Status (17)

Country Link
US (2) US11299487B2 (https=)
EP (1) EP3946599A1 (https=)
JP (1) JP2022527294A (https=)
KR (1) KR20220004982A (https=)
CN (1) CN114025847B (https=)
AU (1) AU2020245489A1 (https=)
BR (1) BR112021018918A2 (https=)
CA (1) CA3133825A1 (https=)
CL (1) CL2021002483A1 (https=)
CO (1) CO2021013171A2 (https=)
CR (1) CR20210499A (https=)
IL (1) IL286511A (https=)
MX (1) MX2021011596A (https=)
PE (1) PE20212177A1 (https=)
PH (1) PH12021552358A1 (https=)
SG (1) SG11202109936YA (https=)
WO (1) WO2020198368A1 (https=)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA202092305A1 (ru) 2018-03-27 2020-12-07 Нейропор Терапиз, Инк. Соединения в качестве модуляторов сигнализации tlr2
IL301574A (en) * 2020-09-25 2023-05-01 Neuropore Therapies Inc Modulators of tlr signaling modulator compounds, compositions comprising same and uses thereof
US20240116962A1 (en) * 2020-12-31 2024-04-11 Tsinghua University Pyridine-2-amine derivative and pharmaceutical composition and use thereof
EP4378932A1 (en) * 2022-11-30 2024-06-05 Universität Bern Novel cd93 inhibitors
WO2025196119A1 (en) 2024-03-22 2025-09-25 Lonza Ltd Continuous deoxyfluorination of ketones using in situ formed dast

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2821116A1 (de) * 1978-05-13 1979-11-15 Bayer Ag Benzofuranyl-benzimidazole
DE2902470A1 (de) * 1979-01-23 1980-07-31 Bayer Ag Cumarin-verbindungen
EP1402887A1 (en) * 2002-09-18 2004-03-31 Jerini AG New compounds for the inhibition of undesired cell proliferation and use thereof
EP2402323A3 (en) * 2004-10-13 2012-05-30 PTC Therapeutics, Inc. Pyrazole or triazole compounds and their use for the manufacture of a medicament for treating somatic mutation-related diseases
MX2009013332A (es) * 2007-06-08 2010-01-25 Mannkind Corp Inhibidores de ire-1 alfa.
WO2008148747A2 (en) * 2007-06-08 2008-12-11 University Of Copenhagen Pdz domain modulators
WO2009002790A2 (en) 2007-06-26 2008-12-31 Bausch & Lomb Incorporated Compositions and methods for treating, reducing, ameliorating, alleviating, or preventing dry eye
MX2011005954A (es) 2008-12-05 2011-10-11 Astellas Pharma Inc Compuesto de 2h-cromeno y su derivado.
CN101805338B (zh) * 2010-04-06 2014-10-15 沈阳药科大学 噁二唑基哌嗪衍生物及其用途
WO2013013504A1 (zh) 2011-07-26 2013-01-31 山东亨利医药科技有限责任公司 替加环素衍生物
US8916705B2 (en) * 2011-10-14 2014-12-23 The Board of Trustees of The University of Illilnois Procaspase-activating compounds and compositions
EP3280256A4 (en) * 2015-04-06 2018-12-12 University of Maryland, Baltimore Small molecule inhibitors of tlr2 signaling
EP3493814A4 (en) 2016-08-03 2020-07-22 Neuropore Therapies, Inc. LIPID-SUBSTITUTED AMINO-1,2 AND 1,3-DIOL COMPOUNDS AS MODULATORS OF TLR2 DIMERIZATION
JP2018135270A (ja) * 2017-02-20 2018-08-30 大日本住友製薬株式会社 イミダゾール誘導体
EA202092305A1 (ru) 2018-03-27 2020-12-07 Нейропор Терапиз, Инк. Соединения в качестве модуляторов сигнализации tlr2

Similar Documents

Publication Publication Date Title
JP2022527294A5 (https=)
JP2024071370A5 (https=)
JP7034935B2 (ja) ピロロ［１，２－ａ］ピリミジニルカルボキサミド化合物および医学的障害の処置におけるその使用
DE69710490T2 (de) Triazolo(4,5-d)pyrimidinyl-derivate und ihre verwendung als medikamente
JP2024520481A5 (https=)
US10399978B2 (en) Imidazopyridine thioglycolic acid derivatives as potent inhibitors of human urate transporter 1
CA3073983C (en) Lysophosphatidic acid receptor 1 (lpar1) inhibitor compounds
JP2020509022A5 (https=)
DE69804966T2 (de) Neue verbindungen
JP2024508789A5 (https=)
JP2024167182A5 (https=)
JP2023547770A5 (https=)
CA2538405A1 (en) Novel compounds
JPH10265454A (ja) ３，７−ジチアプロスタン酸誘導体、それらの製造方法およびそれらを有効成分として含有する薬剤
JP2005508349A5 (https=)
JP2004500426A5 (https=)
JP2007522142A5 (https=)
JP2015508068A5 (https=)
JPH03173874A (ja) 新規複素環化合物
JP2023109937A5 (https=)
JP2007522162A5 (https=)
CA2526991A1 (en) Piperidinium and pyrrolidinium derivatives as ligands for the muscarinic m3 receptor
JP2025502943A5 (https=)
JP2023530708A5 (https=)
JP2025507180A (ja) 肺線維症治療のための薬物の調製におけるヒポキサンチン化合物の使用